ArticlePharmaceutical research2009
Poly (lactide-co-glycolide)-polymethacrylate nanoparticles for intramuscular delivery of plasmid encoding interleukin-10 to prevent autoimmune diabetes in mice.
Article in Pharmaceutical research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 99 citations in OpenAlex.
- Synthetic-polymer-assisted antisense oligonucleotide delivery: targeted approaches for precision disease treatment.Beilstein journal of nanotechnology · 2025Review
- Targeted-Immunomodulatory Nanomedicines for the Treatment of Autoimmune Diseases via Multiple Administration Routes.International journal of nanomedicine · 2025Review
- The Application of Nanomaterials in the Treatment of Pancreatic-Related Diseases.International journal of molecular sciences · 2024Review
- A Systematic Overview of EudragitPharmaceutics · 2023Review
- Particle-Based therapies for antigen specific treatment of type 1 diabetes.International journal of pharmaceutics · 2023Review
- The Progress of Non-Viral Materials and Methods for Gene Delivery to Skeletal Muscle.Pharmaceutics · 2022Review
- Article
- Diseases and conditions that impact maternal and fetal health and the potential for nanomedicine therapies.Advanced drug delivery reviews · 2021Review
- Nano and Microparticle Emerging Strategies for Treatment of Autoimmune Diseases: Multiple Sclerosis and Type 1 Diabetes.Advanced healthcare materials · 2020Review
- Smart Thermosensitive Copolymer Incorporating Chitosan-Zinc-Insulin Electrostatic Complexes for Controlled Delivery of Insulin: Effect of Chitosan Chain Length.International journal of polymeric materials · 2020Article
- Formation and Investigation of Electrospun Eudragit E100/Oregano Mats.Molecules (Basel, Switzerland) · 2019Article
- Stabilized single-injection inactivated polio vaccine elicits a strong neutralizing immune response.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Nanoparticles in tissue engineering: applications, challenges and prospects.International journal of nanomedicine · 2018Review
- Modulating the immune system through nanotechnology.Seminars in immunology · 2017Review
- Enhanced gastric retention and drug releaseDesigned monomers and polymers · 2017Article
- Clearance of pathological antibodies using biomimetic nanoparticles.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Immunosuppressive and anti-inflammatory properties of engineered nanomaterials.British journal of pharmacology · 2014Review
- Chitosans for delivery of nucleic acids.Advanced drug delivery reviews · 2013Review
- Biopolymer-based nanoparticles for drug/gene delivery and tissue engineering.International journal of molecular sciences · 2013Review
- Cationic nanomicelles for delivery of plasmids encoding interleukin-4 and interleukin-10 for prevention of autoimmune diabetes in mice.Pharmaceutical research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purposeDetermine the efficiency of cationic nanoparticles prepared by blending poly (lactide-co-glycolide; PLGA) and methacrylate copolymer (Eudragit(R) E100) to deliver a therapeutic gene encoding mouse interleukin-10, in vitro and in vivo.
methodsNanoparticles prepared with PLGA and E100 were evaluated for delivery of plasmid DNA encoding mouse interleukin-10 in vitro and in vivo in mice upon intramuscular injection. Blood-glucose, serum interferon-gamma levels and histology of pancreas were studied to determine therapeutic efficacy. Histological evaluation of skeletal muscle from the injection site was performed to assess the biocompatibility of nanoparticles.
resultsPLGA/E100 nanoparticles showed endosomal escape evidenced by confocal microscopy and buffering ability. Transfecting HEK293 cells with plasmid-loaded PLGA/E100 nanoparticles resulted in significantly (p < 0.05) greater expression of interleukin-10 compared to PLGA nanoparticles. Mice treated with PLGA/E100 nanoparticles displayed higher serum levels of interleukin-10 and lower blood glucose levels compared to those treated with interleukin-10 plasmid alone or PLGA nanoparticles. High expression of interleukin-10 facilitated suppression of interferon-gamma levels and reduced islet infiltration. Histology of muscle showed that nanoparticles were biocompatible and did not cause chronic inflammatory response.
conclusionsNanoparticles prepared by blending PLGA with methacrylate can efficiently and safely deliver plasmid DNA encoding mouse interleukin-10 leading to prevention of autoimmune diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.